Bayer HealthCare Ranks Top In China
This article was originally published in PharmAsia News
Bayer HealthCare may rank 10 on the global pharmaceutical market, but according to research firm IMS's Q1 2008 figures, the firm's prescription drug revenue was top in China. The result was corroborated by China's R&D-based Pharmaceutical Association Committee's Q1 figures. The acquisition of Topsun Science and Technology's OTC business has raised Bayer's profile in the country and will double its OTC sales. Bayer China discloses that Bayer HealthCare revenue in the country is expected to grow 40 percent this year to over RMB 4.5 billion ($658.8 million). However, there are soft spots such as the gynecology sector, which fails to capitalize on the firm's global strength to translate into significant sales in China. Also, investment in local community health services will need time for the results to be seen. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.